# Case Report: Osteomyelitis in a giant panda (Ailuropoda melanoleuca)

**Authors:** Chengdong Wang, Haidi Yang, Kai Wu, Linhua Deng, Chengyao Li, Rongping Wei, Caiwu Li, Yan Zhu, Ming Wei, Zhi Huang, Yanxi Cheng, Xuemei Chen, Desheng Li

PMC · DOI: 10.3389/fvets.2025.1574668 · Frontiers in Veterinary Science · 2025-10-09

## TL;DR

This case report describes the first instance of osteomyelitis in a giant panda, detailing diagnosis and treatment with antibiotics and chitosan.

## Contribution

The first documented case of osteomyelitis in a giant panda, offering insights for diagnosis and treatment in this species.

## Key findings

- Osteomyelitis was diagnosed in an elderly giant panda using CT and MRI.
- Treatment with rifampicin and chitosan led to significant clinical improvement.
- This case provides guidance for managing similar conditions in captive giant pandas.

## Abstract

Osteomyelitis is an inflammatory disease of bone tissue induced by microbial infection, and poses a significant health burden in humans and animals. The global annual incidence in humans is estimated ~1–10 cases per 100,000 individuals, with notably higher rates observed in high-risk populations. In domestic cubs and companion animals, trauma-related osteomyelitis can occur at an incidence rate ranging from 0.1 to 5%. Although osteomyelitis is well-documented in both human and veterinary medicine, with diverse and complex diagnostic and therapeutic approaches available for human cases, it has not been previously reported in the giant panda (Ailuropoda melanoleuca). This report presents a case of osteomyelitis in an elderly giant panda exhibiting lameness in the left hind limb. Diagnosis was confirmed trough laboratory testing, computed tomography (CT), and magnetic resonance imaging (MRI). The animal underwent a 2-month course of treatment with rifampicin (Guangzhou Baiyunshan Pharmaceutical Group Co., LTD) and medical-grade chitosan (Qingdao Jintieshan Biotechnology Co., LTD), which resulted in significant clinical improvement. This retrospective case analysis provides valuable insights into the clinical diagnosis and management of osteomyelitis in giant pandas and contributes to the foundational knowledge necessary for the prevention and treatment of this condition in captive populations.

## Linked entities

- **Chemicals:** rifampicin (PubChem CID 135398735), chitosan (PubChem CID 129662530)
- **Diseases:** osteomyelitis (MONDO:0005246)
- **Species:** Ailuropoda melanoleuca (taxon 9646)

## Full-text entities

- **Diseases:** trauma (MESH:D014947), inflammatory disease (MESH:D007249), microbial (MESH:D015163), infection (MESH:D007239), Osteomyelitis (MESH:D010019), lameness (MESH:D007794)
- **Chemicals:** chitosan (MESH:D048271), rifampicin (MESH:D012293)
- **Species:** Ailuropoda melanoleuca (giant panda, species) [taxon 9646], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12548475/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12548475/full.md

## References

42 references — full list in the complete paper: https://tomesphere.com/paper/PMC12548475/full.md

---
Source: https://tomesphere.com/paper/PMC12548475